Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine?

OBJECTIVES: The Oxford–AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19, Vaxzevira or Covishield) builds on two decades of research and development (R&D) into chimpanzee adenovirus-vectored vaccine (ChAdOx) technology at the University of Oxford. This study aimed to approximate the funding for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Cross, Samuel, Rho, Yeanuk, Reddy, Henna, Pepperrell, Toby, Rodgers, Florence, Osborne, Rhiannon, Eni-Olotu, Ayolola, Banerjee, Rishi, Wimmer, Sabrina, Keestra, Sarai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704023/
https://www.ncbi.nlm.nih.gov/pubmed/34937701
http://dx.doi.org/10.1136/bmjgh-2021-007321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704023/
https://www.ncbi.nlm.nih.gov/pubmed/34937701
http://dx.doi.org/10.1136/bmjgh-2021-007321

Ejemplares similares